• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nanobiotix S.A.

    6/8/26 1:15:27 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    S-8 1 ef20075653_s8.htm S-8
    As filed with the Securities and Exchange Commission on June 8, 2026
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933


    NANOBIOTIX S.A.
    (Exact name of registrant as specified in its charter)


    France
     
    Not applicable
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. employer identification No.)

    60 rue de Wattignies
    75012 Paris, France
    (Address of Principal Executive Offices)(Zip Code)

    2026 Free Share Plan
    (Full title of the plans)

    Nanobiotix Corporation
    Attn: Bart Van Rhijn
    245 Main Street
    Cambridge, Massachusetts 02142
    +1 617 712 1568
    (Name and address of agent for service) (Telephone number, including area code, of agent for service)



    Copies to:
    Peter E. Devlin
    Shoshana E. Litt
    Jones Day
    250 Vesey Street
    New York, New York 10281
    +1 212 326 3939
    Renaud Bonnet
    Jones Day
    2 rue Saint-Florentin
    75001 Paris, France
    +33 1 56 59 39 39
    François Chamoun
    VP General Counsel
    Nanobiotix S.A.
    60 rue de Wattignies
    75012 Paris, France

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
    Accelerated filer
    ☒
           
    Non-accelerated filer
    ☐
    Smaller reporting company
    ☐
           
       
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    ITEM 3.
    INCORPORATION OF DOCUMENTS BY REFERENCE

    The following documents filed by Nanobiotix S.A. (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

    (a) the Registrant’s Annual Report on Form 20-F (File No. 001-39777) for the year ended December 31, 2025, filed with the Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on March 31, 2026, which contains audited financial statements for the Registrant’s latest fiscal year for which such statements have been filed;

    (b) the Registrant’s Reports on Form 6-K (File No. 001-39777) furnished to the Commission on May 20, 2026 and May 26, 2026 and all other Reports on Form 6-K (File No. 001-39777) that are furnished to the Commission and that are identified in such form as being incorporated by reference in this Registration Statement, since the end of the fiscal year covered by the Registrant’s Annual Report on Form 20-F referred to in (a) above; and

    (c) the descriptions of the Registrant’s American Depositary Shares and Ordinary Shares contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission on December 8, 2020 (File No. 001-39777) under the Exchange Act, including any amendment or report filed for the purpose of updating such description, including the description of the Registrant’s securities included as Exhibit 2.3 to the Registrant’s Annual Report on Form 20-F filed with the Commission on March 31, 2026.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act or furnished by the Registrant and that are specifically identified in such form as being incorporated by reference in this Registration Statement, in each case, on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing of such reports and documents. Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Information subsequently furnished on Form 6-K shall not be deemed incorporated herein by reference unless such Form 6-K expressly provides to the contrary.


    ITEM 4.
    DESCRIPTION OF SECURITIES

    Not applicable.

    ITEM 5.
    INTERESTS OF NAMED EXPERTS AND COUNSEL

    Not applicable.

    ITEM 6.
    INDEMNIFICATION OF DIRECTORS AND OFFICERS

    Under French law, provisions in the By-laws that limit the liability of directors and officers are ineffective. However, French law allows sociétés anonymes to contract for and maintain liability insurance against civil liabilities incurred by any of their directors and officers involved in a third-party action, provided that they acted in good faith and within their capacities as directors or officers of the company. Criminal liability cannot be indemnified under French law, whether directly by the company or through liability insurance. Such rules apply to executive and supervisory board members.

    The Registrant has obtained and maintains customary liability insurance coverage for our supervisory board members and executive board members, including insurance against liability under the Securities Act.

    ITEM 7.
    EXEMPTION FROM REGISTRATION CLAIMED.

    Not applicable.

    ITEM 8.
    EXHIBITS

    The following exhibits are filed herewith:


    Exhibit
    Number
    Description
       
    3.1
    By-laws of the Registrant (English translation) (incorporated herein by reference to Exhibit 1.1 to the Registrant’s Annual Report on Form 20-F (File No. 001-39777) for the year ended December 31, 2025)
       
    4.1
    Deposit Agreement by and among Nanobiotix S.A. and Citibank, N.A., as depositary, and the Holders and Beneficial Owners of American Depositary Shares issued thereunder (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form F-3 (File No. 333-262545))
       
    4.2
    Form of American Depositary Receipt (included in Exhibit 4.1)
       
    5.1*
    Opinion of Jones Day
       
    23.1*
    Consent of KPMG S.A.
       
    23.2*
    Consent of Ernst & Young et Autres
       
    23.3*
    Consent of Jones Day (included in Exhibit 5.1)
       
    24.1*
    Power of Attorney of each of the directors of the Registrant and the principal executive, financial and accounting officers of the Registrant (included on the signature page of this Form S-8)
       
    99.1*
    2026 Free Share Plan
       
    107*
    Filing Fee Table

    * Filed herewith.

    ITEM 9.
    UNDERTAKINGS

    1. The undersigned Registrant hereby undertakes:

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement;

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;


    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Paris, France on June 8, 2026.

     
    NANOBIOTIX S.A.
         
     
    By:
    /s/ Laurent Levy
       
    Name: Laurent Levy, Ph.D.
       
    Title: Chairman of the Executive Board


    POWER OF ATTORNEY

    We, the undersigned directors, officers and/or authorized representative in the United States of Nanobiotix S.A., hereby severally constitute and appoint Laurent Levy and Bart Van Rhijn, and each of them singly, our true and lawful attorneys, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below any and all pre-effective and post-effective amendments to this Registration Statement on Form S-8, under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of Nanobiotix S.A., and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated on June 8, 2026.

    Signature
    Title
       
    /s/ Laurent Levy
    Chairman of the Executive Board
    Laurent Levy
    (Principal Executive Officer)
       
    /s/ Bart Van Rhijn
    Chief Financial and Business Officer and Executive Board Member
    Bart Van Rhijn
    (Principal Financial Officer and Principal Accounting Officer)
       
    /s/ Gary Phillips
    Supervisory Board Chairman
    Gary Phillips
     
       
    /s/ Anne-Marie Graffin
    Supervisory Board Vice Chairwoman
    Anne-Marie Graffin
     
       
    /s/ Alain Herrera
    Supervisory Board Member
    Alain Herrera
     
       
    /s/ Enno Spillner
    Supervisory Board Member
    Enno Spillner
     
       
    /s/ Margaret Liu
    Supervisory Board Member
    Margaret Liu
     
       
     
    Supervisory Board Member
    Anat Naschitz
     


    AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the undersigned as the duly authorized representative in the United States of Nanobiotix S.A. on June 8, 2026.

    NANOBIOTIX CORPORATION
       
    By:
    /s/ Bart Van Rhijn
     
    Name: Bart Van Rhijn
     
    Title: President and Authorized Signatory



    Get the next $NBTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    2/6/2026Buy
    TD Cowen
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings

    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nanobiotix Provides First Quarter 2026 Operational and Financial Update

    Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung cancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy and Oncology (ESTRO)Announced FDA acceptance of a protocol amendment to ongoing pivotal J&J sponsored NANORAY-312 study eliminating the previously planned interim analysis and modifying the final analysis to include fewer events and to be conducted soonerPresented

    6/2/26 4:30:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix Joins the Euronext Tech Leaders Index

    PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. "Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities," said Laurent Levy, chief executive off

    6/2/26 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Announces Closing of Global Offering

    PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces the closing today (the "Closing") of its global offering (the "Global Offering"), including in respect of the earlier total exercise by the underwriters of their option (the "Option") to purchase additional new ordinary shares in the form of additional American Depositary Shares (the "Additional ADSs"). Following the full exercise of the Option, the total number of ordinary shares (e

    5/26/26 4:44:09 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Nanobiotix

    TD Cowen initiated coverage of Nanobiotix with a rating of Buy

    2/6/26 8:11:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Nanobiotix with a new price target

    Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

    8/28/24 7:51:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Nanobiotix with a new price target

    Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00

    12/8/23 8:52:29 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    SEC Filings

    View All

    SEC Form S-8 filed by Nanobiotix S.A.

    S-8 - Nanobiotix S.A. (0001760854) (Filer)

    6/8/26 1:15:27 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    6/5/26 4:15:03 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    6/2/26 4:32:10 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Leadership Updates

    Live Leadership Updates

    View All

    Nanobiotix Joins the Euronext Tech Leaders Index

    PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced its inclusion in the Euronext Tech Leaders segment and Euronext Tech Leaders Index, a Euronext flagship initiative dedicated to increasing the visibility and attractiveness of Europe's leading and high-growth technology companies among international investors. "Nanobiotix was founded on the belief that applying physics to medicine could unlock entirely new therapeutic possibilities," said Laurent Levy, chief executive off

    6/2/26 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris

    PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that following the annual review of the Euronext Paris indices, the Scientific Council of the Indices has decided to admit Nanobiotix to both the CAC Mid 60 and SBF 120 indices. These changes will become effective after the market closes on Friday, December 19, 2025. The CAC Mid 60 and SBF 120 indices represent two of the most widely followed benchmarks for mid-sized and leading liste

    12/15/25 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

    PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the

    6/12/24 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results

    Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of sponsorship for NANORAY-312Strengthened financial position through the closing of a non-dilutive royalty financing with HealthCare Royalty for up to $71 million and an amendment to the gl

    3/31/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

    PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office

    3/26/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

    Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-

    9/17/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/9/24 5:07:50 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/8/24 8:27:02 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/2/24 4:32:27 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care